JP2012521750A5 - - Google Patents

Download PDF

Info

Publication number
JP2012521750A5
JP2012521750A5 JP2012501327A JP2012501327A JP2012521750A5 JP 2012521750 A5 JP2012521750 A5 JP 2012521750A5 JP 2012501327 A JP2012501327 A JP 2012501327A JP 2012501327 A JP2012501327 A JP 2012501327A JP 2012521750 A5 JP2012521750 A5 JP 2012521750A5
Authority
JP
Japan
Prior art keywords
aav
pharmaceutical composition
virion
liver
igf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012501327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012521750A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/ES2010/070184 external-priority patent/WO2010109053A1/es
Publication of JP2012521750A publication Critical patent/JP2012521750A/ja
Publication of JP2012521750A5 publication Critical patent/JP2012521750A5/ja
Pending legal-status Critical Current

Links

JP2012501327A 2009-03-27 2010-03-26 肝硬変及び肝線維症の治療のための方法及び組成物 Pending JP2012521750A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200900846 2009-03-27
ES200900846 2009-03-27
PCT/ES2010/070184 WO2010109053A1 (es) 2009-03-27 2010-03-26 Métodos y composiciones para el tratamiento de cirrosis y fibrosis hepática

Publications (2)

Publication Number Publication Date
JP2012521750A JP2012521750A (ja) 2012-09-20
JP2012521750A5 true JP2012521750A5 (enExample) 2013-05-09

Family

ID=42269789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012501327A Pending JP2012521750A (ja) 2009-03-27 2010-03-26 肝硬変及び肝線維症の治療のための方法及び組成物

Country Status (8)

Country Link
US (2) US20120093775A1 (enExample)
EP (1) EP2412387B1 (enExample)
JP (1) JP2012521750A (enExample)
CN (1) CN102448501A (enExample)
AU (1) AU2010227419A1 (enExample)
CA (1) CA2756596A1 (enExample)
MX (1) MX2011010097A (enExample)
WO (1) WO2010109053A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2453019A4 (en) * 2009-07-10 2013-04-17 Univ Barcelona Autonoma Gene therapy compositions for the prevention and / or treatment of autoimmune diseases
WO2011154308A1 (en) * 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
WO2014012025A2 (en) * 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Igf-1 proteins and therapeutic uses thereof
AU2014354839B2 (en) 2013-11-26 2020-06-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adeno-associated virus vectors for treatment of glycogen storage disease
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
RU2716991C2 (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
WO2016077687A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
CA2969145A1 (en) * 2014-11-26 2016-06-02 The Regents Of The University Of California Therapeutic compositions comprising transcription factors and methods of making and using the same
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
WO2016106303A1 (en) 2014-12-23 2016-06-30 THE UNITED STATES OF AMERICA, as representd by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Adeno-associated virus vectors encoding modified g6pc and uses thereof
EP3384035A4 (en) 2015-12-02 2019-08-07 Voyager Therapeutics, Inc. ASSAYS FOR THE DETECTION OF AAV-NEUTRALIZING ANTIBODIES
MX2018012537A (es) 2016-04-15 2019-02-25 Univ Pennsylvania Terapia de genes para tratar hemofilia a.
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
KR102427379B1 (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US10550405B2 (en) 2017-03-15 2020-02-04 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
NZ756587A (en) * 2017-03-15 2025-12-19 Univ North Carolina Chapel Hill Polyploid adeno-associated virus vectors and methods of making and using the same
JP2020518258A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. 筋萎縮性側索硬化症(als)治療組成物および方法
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. ハンチントン病治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
WO2019028273A1 (en) * 2017-08-02 2019-02-07 Dna2.0, Inc. Dba Atum DNA VECTORS AND ELEMENTS FOR SUSTAINED GENE EXPRESSION IN EUKARYOTIC CELLS
EP3808849A1 (en) 2017-08-03 2021-04-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
US11549125B2 (en) 2017-08-09 2023-01-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Closed-ended, linear, duplex adenoassociated virus DNA, and uses thereof
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
EP3697908A1 (en) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
KR20210019996A (ko) 2018-05-15 2021-02-23 보이저 테라퓨틱스, 인크. 파킨슨병의 치료를 위한 조성물 및 방법
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
CN111135311B (zh) * 2018-11-02 2023-06-13 中国科学院分子细胞科学卓越创新中心 Ecm1在预防和/或治疗肝纤维化相关疾病中的应用
AU2019407921A1 (en) * 2018-12-19 2021-06-10 Versameb Ag RNA encoding a protein
US20230295238A1 (en) * 2020-07-23 2023-09-21 The Scripps Research Institute Insulin receptor-mediated enhancement of gene transfer
CN116997656A (zh) * 2021-02-15 2023-11-03 生物马林药物股份有限公司 富含组氨酸的肽作为用于rAAV和rBV生产的转染试剂的用途
WO2022261663A1 (en) * 2021-06-11 2022-12-15 Spark Therapeutics, Inc. Aav vector column purification methods
NL2033264B1 (en) * 2022-10-10 2024-04-26 Amarna Holding B V Composition and method for the production of polyomaviral vector particles
CN115656517B (zh) * 2022-10-24 2023-09-12 南方医科大学南方医院 一种用于肝硬化食管胃静脉曲张的诊断和分层的蛋白标记物及其应用
CN116555266B (zh) * 2023-06-09 2024-11-12 呈诺再生医学科技(北京)有限公司 肝脏特异性表达的重组启动子和载体及其在肝脏相关疾病治疗中的应用
CN118430796A (zh) * 2024-07-05 2024-08-02 杭州生奥信息技术有限公司 基于血液生化指标的肝纤维化无创诊断方法和系统

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0208491B1 (en) 1985-07-03 1993-08-25 Genencor International, Inc. Hybrid polypeptides and process for their preparation
ATE81779T1 (de) 1985-08-22 1992-11-15 Gropep Pty Ltd Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren.
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
ATE116335T1 (de) 1987-12-24 1995-01-15 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
PT728214E (pt) 1993-11-09 2004-11-30 Ohio Med College Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
CA2207927A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
WO1998009524A1 (en) * 1996-09-06 1998-03-12 Chiron Corporation Methods and compositions for liver specific delivery of therapeutic molecules using recombinant aav vectors
WO1998011244A2 (en) 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Aav4 vector and uses thereof
JP2001506132A (ja) 1996-12-18 2001-05-15 ターゲティッド ジェネティクス コーポレイション Aavベクターの産生における使用のためのリコンビナーゼ活性化可能aavパッケージングカセット
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6251677B1 (en) 1997-08-25 2001-06-26 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
WO1999061601A2 (en) 1998-05-28 1999-12-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aav5 vector and uses thereof
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
ATE362542T1 (de) 1998-11-05 2007-06-15 Univ Pennsylvania Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
US6387368B1 (en) 1999-02-08 2002-05-14 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
ATE318923T1 (de) 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
WO2003042361A2 (en) 2001-11-09 2003-05-22 Government Of The United States Of America, Department Of Health And Human Services Production of adeno-associated virus in insect cells
AU2003212708A1 (en) 2002-03-05 2003-09-16 Stichting Voor De Technische Wetenschappen Baculovirus expression system
SI1633772T1 (sl) 2003-06-19 2016-06-30 Genzyme Corporation AAV virioni z zmanjšano imunoreaktivnostjo in uporaba za ta namen
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
EP2311966A3 (en) 2005-10-20 2012-09-05 Amsterdam Molecular Therapeutics (AMT) B.V. Improved AAV vectors produced in insect cells
US20080045609A1 (en) * 2006-03-12 2008-02-21 Devore Dianna L Methods and therapeutics to facilitate liver repair
CN103849629B (zh) 2006-06-21 2017-06-09 尤尼克尔Ip股份有限公司 具有经修饰的用于在昆虫细胞中产生aav的aav‑rep78翻译起始密码子的载体
AR066354A1 (es) * 2007-05-01 2009-08-12 Genzyme Corp La terapia sistematica con factor-1 de crecimiento de tipo insulina reduce la neuropatia periferica diabetica y mejora la funcion renal en la nefropatia diabetica

Similar Documents

Publication Publication Date Title
JP2012521750A5 (enExample)
TWI756185B (zh) 腺相關病毒因子viii載體、相關病毒粒子及包含其之治療調配物
US20220331409A1 (en) Factor ix gene therapy
ES2640586T3 (es) Secuencias del factor VIII
JP2020522269A5 (enExample)
JP2024028696A (ja) 幼若対象におけるaavベクターの安定的発現
JP2020096587A (ja) キャプシド
JP2018531609A5 (enExample)
RU2017125234A (ru) Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний
WO2019060454A3 (en) Adeno-associated virus variant capsids and methods of use thereof
JP2011101646A5 (enExample)
JP2018522529A5 (enExample)
RU2021102893A (ru) Модифицированные гены атаксии фридрейха и векторы для генной терапии
JP7558535B2 (ja) アルデヒドデヒドロゲナーゼ欠損症の治療のための遺伝子治療
CN112166195A (zh) Aav嵌合体
JP2022545121A (ja) Aav5の単離修飾vp1カプシドタンパク質
JP2021512601A5 (enExample)
JP2022525302A5 (enExample)
JP2017529395A5 (enExample)
JP2023524414A5 (enExample)
WO2021041787A1 (en) Compositions and methods for treating viral infections
US12319714B2 (en) Compositions and methods for treating viral infections
JP2018536432A5 (enExample)
CN120359235A (zh) 用于治疗心脏病和与心脏功能障碍相关的疾病的具有降低的肝脏嗜性和增强的心脏细胞转导的重组腺相关病毒基因治疗载体
Wang et al. LRP6-Guided Engineering of AAV9 Variants with Enhanced Blood-Brain Barrier Penetration and Reduced Liver Tropism in Non-Human Primates